Moving forward with Takeda's live chimeric tetravalent dengue vaccine
Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
2017
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/83617 http://hdl.handle.net/10220/42732 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100 million individuals per year,1 the approval of the first dengue vaccine developed by Sanofi Pasteur (CYD-TDV) was a welcome step forward.2 However, the first vaccine does not present a simple solution. |
|---|